01. Doctor Overview

Doctor Overview

Dr. Ramaswamy Govindan is a medical oncologist at the Alvin J. Siteman Cancer Center inSaint Louis, Missouri。他还是Anheuser Busch医学肿瘤学的主席，华盛顿大学医学院医学肿瘤学系医学教授和医学肿瘤学主任。Govindan博士拥有内科，血液学和医学肿瘤学的董事会认证，并专门研究肺和胸腔癌。

Dr. Govindan’s research interests include the management and间皮瘤的治疗万博专业版。He serves as a leading researcher at both Washington University School of Medicine and Siteman Cancer Center. He studiesgene therapyand personalized medicine, and has a specific interest in using specialized treatment methods based on an individual’s tumor genomic profile. Dr. Govindan leads a clinical trial called ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial) that is facilitated on a national level. The trial is designed to provide patients with alternative, targeted treatment for advanced lung cancers.

02. Fast Facts

Doctor Fast Facts

主要专业：Oncology

其他兴趣和专业：Oncology, general oncology, hematologic oncology, lung cancer, mesothelioma, esophageal cancer, non-small cell lung cancer and thoracic cancer.

Certifications, Awards & Accolades:Anheuser Busch赋予医学肿瘤学主席，美国内科医学肿瘤学委员会，美国内科血液学委员会，美国内科医学委员会，内科委员会，美国临床肿瘤学会（ASCO）成员，Alton Ochsner，Alton Ochsner与吸烟和疾病有关的奖励

教育与经验：

• Medical Degree from the University of Madras
• Residency for Internal Medicine at Jawaharlal Institute of Postgraduate Medical Education and Research
• Internship for Internal Medicine at Michael Reese Hospital and Medical Center
• Residency for Internal Medicine at Michael Reese Hospital and Medical Center
• 华盛顿大学血液学/肿瘤学奖学金

03. Publications

Publications

磅/ II期研究的pan-cyclin-dependent基那se inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer。Lung Cancer。September 2018;123:14-21. doi:10.1016/j.lungcan.2018.04.022

Adjuvant Chemotherapy for Patients with T2N0M0 NSCLC。Journal of Thoracic Oncology。October 2016;11(10):1729-35. doi:10.1016/j.jtho.2016.05.022

The Immune Landscape of Cancer。Immunity。2018年4月;48（4）：812-830.E14。doi：10.1016/j.immuni.2018.03.023